Jason Legg
Overview
Explore the profile of Jason Legg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
652
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dent R, Joshi R, Djedjos C, Legg J, Elliott M, Geller M, et al.
Springerplus
. 2016 Apr;
5:300.
PMID: 27066336
Evolocumab has been shown to consistently reduce low-density lipoprotein cholesterol (LDL-C) across populations. The phase 3 studies included administration in the home-use and in-clinic settings but did not specifically evaluate...
2.
Sabatine M, Giugliano R, Wiviott S, Raal F, Blom D, Robinson J, et al.
N Engl J Med
. 2015 Mar;
372(16):1500-9.
PMID: 25773607
Background: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies. We conducted two extension studies to obtain...
3.
Johnson P, Bancroft T, Barron R, Legg J, Li X, Watson H, et al.
Value Health
. 2014 Jun;
17(4):380-9.
PMID: 24968998
Objectives: Rising out-of-pocket costs for cancer patients have increased shared decision making. Clinical guidelines recommend prophylactic granulocyte colony-stimulating factor (G-CSF) for patients receiving chemotherapy with a 20% or greater risk...
4.
Weycker D, Barron R, Edelsberg J, Kartashov A, Legg J, Glass A
BMC Health Serv Res
. 2014 Apr;
14:189.
PMID: 24767095
Background: To examine duration of daily filgrastim prophylaxis, and risk and consequences of chemotherapy-induced neutropenic complications (CINC) requiring inpatient care. Methods: Using a retrospective cohort design and US healthcare claims...
5.
Weycker D, Barron R, Kartashov A, Legg J, Lyman G
J Oncol Pharm Pract
. 2013 Jul;
20(3):190-8.
PMID: 23824496
Objective: To examine the incidence, treatment, and consequences of febrile neutropenia across inpatient and outpatient care settings. Methods: Data were obtained from Humedica's National Electronic Health Record-Derived Longitudinal Patient-Level Database...
6.
Reitan J, van Breda A, Corey-Lisle P, Shreay S, Cong Z, Legg J
Clin Drug Investig
. 2013 Apr;
33(5):383-9.
PMID: 23553358
Background: Erythropoiesis-stimulating agents (ESAs) are used for the management of anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitant myelosuppressive chemotherapy. Assessing the impact...
7.
Weycker D, Sofrygin O, Seefeld K, Deeter R, Legg J, Edelsberg J
BMC Health Serv Res
. 2013 Feb;
13:60.
PMID: 23406481
Background: Healthcare claims databases have been used in several studies to characterize the risk and burden of chemotherapy-induced febrile neutropenia (FN) and effectiveness of colony-stimulating factors against FN. The accuracy...
8.
Pirker R, Pirolli M, Quigley J, Hulnick S, Legg J, Collins H, et al.
Support Care Cancer
. 2012 Oct;
21(4):987-92.
PMID: 23096072
Purpose: The aim of this study was to examine the rate and timing of hemoglobin decline from <10 g/dL to <9 g/dL in cancer patients receiving chemotherapy. Methods: Pooled data...
9.
Kozma C, Dickson M, Chia V, Legg J, Barron R
J Oncol Pract
. 2012 Sep;
8(3):149-55.
PMID: 22942808
Purpose: Neutropenic complications (NCs) after myelosuppressive chemotherapy are associated with significant morbidity and mortality. We described NC rates by using US hospital discharge data. Materials And Methods: This cross-sectional analysis...
10.
Stasi R, Murali M, Michel M, Viallard J, Giagounidis A, Janssens A, et al.
Int J Hematol
. 2012 May;
96(1):26-33.
PMID: 22562409
Romiplostim increases platelet counts and reduces the risk of bleeding in patients with immune thrombocytopenia (ITP). This post hoc analysis compared the effect of romiplostim versus medical standard of care...